Role of Placental Insufficiency in Preeclampsia, IUGR, and Fetal Programming of H
胎盘功能不全在先兆子痫、IUGR 和 H 胎儿编程中的作用
基本信息
- 批准号:8301922
- 负责人:
- 金额:$ 23.1万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-04-01 至 2014-03-31
- 项目状态:已结题
- 来源:
- 关键词:AffectAngiogenic FactorAngiotensin IIAngiotensinogenArteriesBloodBlood VesselsBlood VolumeBlood flowClinicalDataDiseaseDoppler UltrasoundEndothelial CellsEtiologyFetal Growth RetardationFunctional disorderFutureGene DeliveryGenesGenetically Engineered MouseGenotypeGrowthHaplotypesHormonesHornsHumanHypertension induced by pregnancyImageIschemiaKidney DiseasesLeadLifeLuciferasesMeasuresMethodsMicrobubblesModelingMolecularMusOutcomePathologyPathway interactionsPatientsPhysiologicalPlacentaPlacental InfarctionPlacental InsufficiencyPlayPre-EclampsiaPregnancyPregnancy ComplicationsPregnancy OutcomeProcessProteinuriaRelative (related person)Renal glomerular diseaseReporterReportingRoleScreening procedureSeptic ToxemiaSerumSimulateSpiral Artery of the EndometriumSystemTechnologyTestingTimeTissuesTransfectionTransgenic MiceTransgenic OrganismsUltrasonographyUmbilical cord structureUp-RegulationUterusVEGFA geneVariantVascular Endothelial Growth Factor ReceptorVascular Endothelial Growth FactorsVascular remodelingWomandisorder riskeffective therapyfetalfetal programminggene delivery systemhuman diseasein vivoinnovationmouse modelnovelnovel strategiespreventpromoterreconstructionresearch study
项目摘要
DESCRIPTION (provided by applicant): Pregnancy-induced hypertension (preeclampsia, toxemia) and fetal growth restriction (IUGR) are common and life-threatening complications of pregnancy. Currently, there are no effective screening tests and there are no effective treatments other than early delivery of the baby. Preeclampsia and IUGR share very similar uteroplacental pathology. Their placentas are often growth restricted, they have placental infarctions, and sections reveal abnormal placental architectural. Doppler ultrasound often reveals absent end-diastolic flow in the fetal umbilical cord, which is an indirect sign of uteroplacental insufficiency. Moreover, women with preeclampsia and/or IUGR demonstrate upregulation of placental s-flt1 (vascular endothelial growth factor [VEGF] receptor), a sign of relative ischemia, and months before the clinical presentation of these diseases. These observations suggest that abnormal uteroplacental blood flow may play a key role in preeclampsia and IUGR. To test this hypothesis, we validated a genetically engineered mouse model that simulates a common human angiotensinogen (AGT) variant that is associated with preeclampsia and IUGR. This "physiologic" mouse model fails to increase its blood volume during pregnancy, similar to women with preeclampsia. It also demonstrates multiple features of uteroplacental insufficiency such as fetal growth restriction, absent diastolic flow by cord Doppler, and elevated sflt-1. We propose to use a novel quantitative microbubble-enhanced imaging system to correlate uteroplacental blood flow in vivo with maternal and fetal outcomes in our model. In addition, to better understand the role of VEGF and sflt-1 in the pathophysiology of placental insufficiency, we will employ our microbubble-conjugated gene delivery system to specifically increase VEGF expression at the uteroplacental interface. These experiments will allow us to test for a relationship between VEGF levels, uteroplacental blood flow, and pregnancy outcomes in our model compared to normal controls. In summary, our novel approach uses a genetically engineered mouse model and an innovative new microbubble technology to measure uteroplacental blood flow and directly deliver treatment to the placenta. Our results will help us better understand the underlying pathology of these serious human diseases and are the first steps toward future studies investigating molecular mechanisms and potential applications in women.
PUBLIC HEALTH RELEVANCE: Preeclampsia and fetal growth restriction are common and life-threatening complications of pregnancy, which often occur together and likely share a common underlying pathophysiology. Currently, there are no effective tests to determine which pregnancies are at risk for these diseases, and there are no effective treatments other than early delivery of the baby. Our novel approach uses a genetically engineered mouse model and an innovative new microbubble technology to test whether abnormal uteroplacental blood flow may be an underlying cause of these diseases and whether increasing VEGF expression in uterine spiral arteries ameliorates or exacerbates the condition.
描述(由申请人提供):妊娠高血压(子痫前期、毒血症)和胎儿生长受限(IUGR)是常见的危及生命的妊娠并发症。目前,没有有效的筛查测试,也没有有效的治疗方法,只能提前分娩。子痫前期和IUGR具有非常相似的子宫-胎盘病理。他们的胎盘通常生长受限,有胎盘梗死,切片显示异常的胎盘结构。多普勒超声经常显示胎儿脐带舒张末血流缺失,这是子宫胎盘功能不全的间接迹象。此外,患有先兆子痫和/或IUGR的妇女在出现这些疾病的临床表现前几个月就表现出胎盘s-flt1(血管内皮生长因子[VEGF]受体)的上调,这是相对缺血的迹象。这些观察结果表明,异常子宫胎盘血流可能在子痫前期和IUGR中起关键作用。为了验证这一假设,我们验证了一个基因工程小鼠模型,该模型模拟了与子痫前期和IUGR相关的常见人类血管紧张素原(AGT)变异。这种“生理性”小鼠模型在怀孕期间无法增加其血容量,这与患有先兆子痫的女性相似。它还显示了子宫胎盘功能不全的多种特征,如胎儿生长受限,脐带多普勒无舒张期血流,sflt-1升高。我们建议在我们的模型中使用一种新的定量微泡增强成像系统来关联体内子宫胎盘血流与母体和胎儿结局。此外,为了更好地了解VEGF和sflt-1在胎盘功能不全病理生理中的作用,我们将利用我们的微泡结合基因传递系统特异性地增加子宫-胎盘界面VEGF的表达。这些实验将使我们能够在我们的模型中与正常对照组比较,测试VEGF水平、子宫胎盘血流和妊娠结局之间的关系。总之,我们的新方法使用了一种基因工程小鼠模型和一种创新的新微泡技术来测量子宫胎盘血流并直接向胎盘输送治疗。我们的研究结果将帮助我们更好地理解这些严重人类疾病的潜在病理,是未来研究分子机制和女性潜在应用的第一步。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Terry Knud Morgan其他文献
Terry Knud Morgan的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Terry Knud Morgan', 18)}}的其他基金
Proteomic Analysis of Placental Extracellular Vesicles Isolated from Maternal Blood by High Resolution Flow Cytometry
通过高分辨率流式细胞术对母血中分离的胎盘细胞外囊泡进行蛋白质组学分析
- 批准号:
9353841 - 财政年份:2016
- 资助金额:
$ 23.1万 - 项目类别:
Placental Insufficiency in Transgenic Mouse Model of Preeclampsia and IUGR
先兆子痫和 IUGR 转基因小鼠模型中的胎盘功能不全
- 批准号:
8446286 - 财政年份:2012
- 资助金额:
$ 23.1万 - 项目类别:
相似海外基金
How angiogenic factor induces immunosuppressive cells to tumor microenvironment
血管生成因子如何诱导免疫抑制细胞进入肿瘤微环境
- 批准号:
22KJ0818 - 财政年份:2023
- 资助金额:
$ 23.1万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Validation of Adenylosuccinate as a Novel Endogenous Pro-Angiogenic Factor in the Brain
腺苷琥珀酸作为大脑中新型内源性促血管生成因子的验证
- 批准号:
10711027 - 财政年份:2021
- 资助金额:
$ 23.1万 - 项目类别:
Validation of Adenylosuccinate as a Novel Endogenous Pro-Angiogenic Factor in the Brain
腺苷琥珀酸作为大脑中新型内源性促血管生成因子的验证
- 批准号:
10297199 - 财政年份:2021
- 资助金额:
$ 23.1万 - 项目类别:
Validation of Adenylosuccinate as a Novel Endogenous Pro-Angiogenic Factor in the Brain
腺苷琥珀酸作为大脑中新型内源性促血管生成因子的验证
- 批准号:
10625314 - 财政年份:2021
- 资助金额:
$ 23.1万 - 项目类别:
Validation of Adenylosuccinate as a Novel Endogenous Pro-Angiogenic Factor in the Brain
腺苷琥珀酸作为大脑中新型内源性促血管生成因子的验证
- 批准号:
10405070 - 财政年份:2021
- 资助金额:
$ 23.1万 - 项目类别:
Physiological role of anti-angiogenic factor thrombospondin in the regulation of endometrial function during early pregnancy in cattle
抗血管生成因子血小板反应蛋白在牛妊娠早期子宫内膜功能调节中的生理作用
- 批准号:
20K06385 - 财政年份:2020
- 资助金额:
$ 23.1万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Elucidation of lymphangiogenic regulatory mechanism of angiogenic factor CCN2 through tumor-associated macrophage
阐明血管生成因子CCN2通过肿瘤相关巨噬细胞的淋巴管生成调节机制
- 批准号:
17K11866 - 财政年份:2017
- 资助金额:
$ 23.1万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Elucidation of vascular stabilization mechanism by anti-angiogenic factor vasohibin-1
抗血管生成因子 vasohibin-1 阐明血管稳定机制
- 批准号:
15K20874 - 财政年份:2015
- 资助金额:
$ 23.1万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
angiogenic therapy for cerebral infarction with anti^sense homology derived peptide targeting angiogenic factor
靶向血管生成因子的反义同源肽治疗脑梗死
- 批准号:
15K15523 - 财政年份:2015
- 资助金额:
$ 23.1万 - 项目类别:
Grant-in-Aid for Challenging Exploratory Research
The development of the anti-angiogenic factor VEGF-A165b quantification methods for cardiovascular disease.
心血管疾病抗血管生成因子 VEGF-A165b 定量方法的开发。
- 批准号:
26860367 - 财政年份:2014
- 资助金额:
$ 23.1万 - 项目类别:
Grant-in-Aid for Young Scientists (B)